Nasdaq Helsinki Ltd: FONDIA OYJ: SHARES SUBSCRIBED WITH OPTION RIGHTS
NOTICE, MAY 27, 2021 SHARES
FONDIA OYJ: SHARES SUBSCRIBED WITH OPTION RIGHTS
A total of 6,363 shares will be traded as old shares as of May 28, 2021 on
First North Growth Market Finland.
Identifiers of Fondia Oyj s share:
Trading code: FONDIA
ISIN code: FI4000232913
Orderbook id: 135505
Number of shares: 3,953,134
Nasdaq Helsinki Oy, Surveillance, survo@nasdaq.com, +358 9 6166 7260
Kostenloser Wertpapierhandel auf Smartbroker.de
FNRD-2.621.0
Wie bewerten Sie die aktuell angezeigte Seite?sehr gut123456schlechtProblem melden
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen,
SciBase - Interim report
January 1 - March 31, 2021
The first quarter in figures
Net sales amounted to TSEK 2,562 (2,469).
The loss after tax amounted to TSEK 8,153 (8,936).
The loss per share amounted to SEK 0.15 (0.54).
The cash flow from current operations was negative in the amount of TSEK 9,473 (7,893).
The gross margin reached 52.7% (54.0%).
Electrode sales volume increased by 14% and reached 7,496 (6,562) units, a new quarterly high. Repeat sales of electrodes to existing customers increased by 18%.
Important events during the quarter
Covid-19 continues to affect sales and the market situation remains difficult to predict going forward, due to ongoing lockdowns and reduced marketing activities. Sales in the company s key market Germany increased by 3%(cleared for currency effects +9%) while overall sales increased by 3% (cleared for currency effects +9%).
Share this article
STOCKHOLM, May 11, 2021 /PRNewswire/
SciBase Holding AB ( SciBase ) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the launch of the new Non-Melanoma Skin Cancer (NMSC) clinical application following the completion of their MDR certification process.
SciBase s strategy is to leverage the Nevisense technology platform to launch additional clinical applications and products. The first clinical application or indication to be added is NMSC, initially for Nevisense 3.0.
There are two types of skin cancer: melanoma and non-melanoma skin cancer (NMSC). NMSC is more than ten times more prevalent than melanoma and comes itself in primarily two forms: basal cell carcinoma and squamous cell carcinoma. Although NMSC is less harmful and deadly than melanoma, it is still important that it is detected early and is managed with the most appropriate therapy. Because Dermatologists see many more patients with s
SciBase receives important European MDR certification
STOCKHOLM, May 10, 2021 /PRNewswire/
SciBase Holding AB ( SciBase ) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that it has been granted certification under the new Medical Device Regulation (MDR).
MDR is a set of mandatory legal requirements central for all companies selling medical devices in the EU. The new regulation comes into effect on May 26
th. SciBase is one of very few medical device manufacturers to have completed the MDR certification, after an intensive two year process. With the MDR Certification in place SciBase can release new products, indications and functionality such as their new Non-melanoma Skin cancer (NMSC) application.
Nasdaq Helsinki Ltd: VINCIT OYJ: SHARES SUBSCRIBED WITH OPTION RIGHTS
NOTICE, MAY 07, 2021 SHARES (Record Id 170949)
VINCIT OYJ: SHARES SUBSCRIBED WITH OPTION RIGHTS
A total of 8,712 shares will be traded as old shares as of May 10, 2021 on
First North Growth Market Finland.
Identifiers of Vincit Oyj s share:
Trading code: VINCIT
ISIN code: FI4000185533
Orderbook id: 127211
Number of shares: 12,276,333
Nasdaq Helsinki Oy, Surveillance, survo@nasdaq.com, +358 9 6166 7260
Kostenloser Wertpapierhandel auf Smartbroker.de
FNRD-2.621.0
Wie bewerten Sie die aktuell angezeigte Seite?sehr gut123456schlechtProblem melden
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen.